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Background: Primary Sjögren’s Syndrome (PSS) mainly affects women (9:1 female:male ratio) and is one of the
commonest autoimmune diseases with a prevalence of 0.1 – 0.6% of adult women. For patients with PSS there is
currently no effective therapy that can alter the progression of the disease. The aim of the TRACTISS study is to
establish whether in patients with PSS, treatment with rituximab improves clinical outcomes.
Methods/design: TRACTISS is a UK multi-centre, double-blind, randomised, controlled, parallel group trial of 110
patients with PSS. Patients will be randomised on a 1:1 basis to receive two courses of either rituximab or placebo
infusion in addition to standard therapy, and will be followed up for up to 48 weeks. The primary objective is to
assess the extent to which rituximab improves symptoms of fatigue and oral dryness. Secondary outcomes include
ocular dryness, salivary flow rates, lacrimal flow, patient quality of life, measures of disease damage and disease
activity, serological and peripheral blood biomarkers, and glandular histology and composition.
Discussion: The TRACTISS trial will provide direct evidence as to whether rituximab in patients with PSS leads to an
improvement in patient symptoms and a reduction in disease damage and activity.
Trial registration: UKCRN Portfolio ID: 9809 ISRCTN65360827.
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Primary Sjögren’s Syndrome (PSS) mainly affects women
(9:1 female:male ratio) and is one of the commonest
autoimmune diseases with a prevalence of 0.1 – 0.6% of
adult women in community studies using the American-
European Consensus Group (AECG) criteria [1-3]. PSS is
characterised by a combination of features including oral
and ocular dryness, which can be disabling symptoms,* Correspondence: medsbro@leeds.ac.uk
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stated.ocular signs i.e. objective evidence for ocular involvement,
abnormal appearance of salivary glands, salivary gland
involvement and presence of antibodies to Ro and/or La.
PSS patients may also experience severe, variable & unpre-
dictable fatigue, which is similar in character and severity
to that of patients with Systemic Lupus Erythematosus
(SLE) [4]. Similarly, fibromyalgia (widespread chronic pain,
unrefreshing sleep and 11 out of 18 tender trigger points)
is found in 5% of PSS patients, again comparable to SLE
[4]. Organ-specific systemic involvement is observed
in 5-20% of patients. This includes rashes, peripheral
neuropathy, non-erosive arthritis, interstitial cystitis,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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evidence of B-cell hyper-reactivity with anti-Ro/La anti-
bodies & hypergammaglobulinaemia.
For patients with PSS there is currently no effective
therapy that can alter the progress of the disease. Symp-
tomatic therapies for dry eyes, such as artificial tears, are
reasonably effective. By contrast, therapies for dry mouth
(sprays, gels or lozenges/pastilles) are poorly effective for
most people. There is no effective therapy for fatigue.
Hydroxychloroquine and/or low dose prednisolone are
often used in mild disease. At the severe end e.g. progressive
neuropathy, IV methylprednisolone, cyclophosphamide,
azathioprine, ciclosporine, mycophenolate or chlorambucil
may be used.
Rituximab (MabThera®/Rituxan®) is a chimeric mouse/
human monoclonal antibody against human CD20, a
non-glycosylated transmembrane phosphoprotein, expressed
on pre-B and mature B-lymphocytes. Rituximab depletes
B cells by several potential mechanisms, including
complement-mediated lysis, antibody-dependent cellular
cytotoxicity (ADCC)-mediated killing, and apoptosis.
Treatment with rituximab induces a rapid and sus-
tained depletion of B cells. Median peripheral B-cell
counts decline below normal following completion of
the first dose, with recovery beginning after 6 months.
B-cell levels return to normal between 9 and 12 months
following completion of therapy.
Rituximab is currently approved for the treatment of
relapsed or refractory non-Hodgkin’s lymphoma (NHL),
chronic lymphocytic leukemia (CLL), and in combination
with methotrexate (MTX) for the treatment of Rheumatoid
Arthritis (RA) patients who inadequately respond to one
or more anti-tumor necrosis factor (anti-TNF) therapies.
There is supportive evidence for the beneficial effects
of rituximab in treating PSS patients from several small
studies [5-10]. There is also early data that in patients
with high pre-treatment levels of B-cell Activating
Factor/B Lymphocyte Stimulator (BAFF/BLyS), B-cell
recovery occurs sooner [11] following rituximab therapy
and also that BAFF/BLyS levels increase following B-cell
depletion [12]. A multicentre parallel-group randomised
double-blind placebo controlled study of rituximab in 120
patients with PSS in France has completed [13]. In this
study patients were randomly allocated to receive one
course of rituximab or placebo infusions at weeks 0 and
2, with follow-up at 24 weeks. The primary outcome
was a 30 mm improvement in two out of four visual
analogue scales (VAS – Range 0-100 mm) (patient global
assessment of disease activity, joint pain, fatigue and
dryness) at 24 weeks. Preliminary results of the trial
reveal that it failed to meet its primary endpoint over
the 24 week period, potentially suggesting that the
TRACTISS trial is justified in assessing the efficacy of
two courses of treatment, each with two doses, spacedtwo weeks apart which is in contrast to the French trial
which administered only one course of two doses. Fur-
thermore, the TRACTISS trial is intended to be closely
aligned to the design of the French study to permit a
meta-analysis. As a consequence the eligibility criteria and
potential impact on patient recruitment was modelled from
data in the United Kingdom Primary Sjögren's Syndrome
Registry (UKPSSR) [14] to ensure a robust recruitment
strategy could be employed.
T-cell phenotypes and transcriptional profiles have been
reported to be abnormal in the peripheral blood and
affected tissues of patients with PSS, where T cells
comprise the majority of infiltrating lymphocytes. B
cells and T cells interact in lymphoid organs and within
the inflamed tissue, suggesting that any clinical effects
of B-cell depletion may be due to indirect effects on T
cells. In a subset of patients in TRACTISS, T cells will be
isolated from peripheral blood and their transcriptional
profiles compared to healthy and disease controls to
explore whether abnormal T-cell transcriptional activity
at baseline (a) normalises following Rituximab therapy;
and (b) predicts the patients’ subsequent clinical course.
The results will also be compared with transcriptional
activity of lesional T cells in an attempt to find periph-
eral blood correlates of T cell-mediated damage to
lesional tissue.
PSS imposes a cost burden on patients and the health
service. Annual direct healthcare costs of PSS have been
estimated at £2,188 per annum per patient, comparable
to a cost of £2,693 per annum per patient for those with
RA [15]. Although this study predated the widespread
use of biologic therapy in RA it suggests that treating
PSS currently costs 50-80% of the total cost of treating
an RA patient and further supports the observation that
untreated PSS has a significant health economic impact.
Methods/design
Trial aims and objectives
The main aim of the study is to determine whether use
of rituximab is of benefit to patients with PSS.
Primary objective
To assess whether rituximab, compared with placebo in-
fusion, improves symptoms of fatigue and oral dryness
measured by visual analogue scales (VAS) in patients
with PSS.
Secondary objectives
To assess whether rituximab, compared with placebo:
 Increases salivary and lacrimal flow.
 Produces improvement in serological and peripheral
blood inflammatory features.
 Improves quality of life and disease activity indices.
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 Is cost effective.
To further validate questionnaires measuring disease ac-
tivity and patient symptoms currently in development for
use in the assessment of Sjögren’s Syndrome.
Sub-studies objectives
To conduct a central analysis of local and systemic T-cell
abnormalities in patients with PSS and their response to
B-cell depletion:
 To compare peripheral blood T-cell transcriptional
signatures in PSS patients with healthy and
disease controls.
 To compare peripheral blood T-cell transcriptional
signatures in PSS patients’ pre- and post-
B-cell depletion.
 To characterise tissue distribution, phenotype, and
gene expression of lesional T-cells in PSS patients
pre- and post-B-cell depletion.
Optional labial gland biopsy and imaging
 To conduct a central review to assess whether
rituximab has an effect on glandular histology and
to determine whether ultrasound imaging is an
effective tool in determining treatment response.
Trial design
The TRACTISS trial is a multi-centre, double-blind, ran-
domised, controlled, parallel group trial in 110 patients
with primary Sjögren’s Syndrome exhibiting both fatigue
and oral dryness to evaluate the use of two courses of
rituximab compared to placebo infusion, in addition to
standard therapy. Patients will be followed-up for up to
48 weeks (see Figure 1).
Recruitment
Participant recruitment is planned over a 36-month
period from a maximum of 25 centres across the United
Kingdom. Patients will be approached by a research clin-
ician during standard clinic visits. Alternatively patients
may be identified by case note review and the UKPSSR
and sent a Patient Invitation Letter inviting them to take
part. Patients will be provided with verbal and written
details about the trial (detailed Patient Information
Sheet). Patients will be given at least 24 hours to read
the information to consider participation. Patients will
be invited to provide written informed consent before
being formally assessed for eligibility by the Principal
Investigator or any other qualified member of the trial
team. Eligible patients from centres that have access to
ultrasound and also have the facilities to perform glandbiopsies will be invited to take part in the optional sub-
studies to obtain minor labial gland biopsies and labial
salivary gland ultrasound scans.
Screening
Patients will be registered for the study before any trial-
related invasive or non-invasive procedures are performed.
All patients will undergo a screening assessment within 28
days prior to the start of treatment to determine eligibility
for the study. Patients need to satisfy all of the study inclu-
sion criteria and not have any of the exclusion criteria
in Table 1. Patients who are initially ineligible for the
trial may be re-screened at a later date. This applies to
patients with low or no salivary flow, have no systemic
features (but have disease duration of 10+ years) or
have a fatigue and/or oral dryness rated as below 5 on
a Likert scale of 0–10.
Randomisation
Following confirmation of eligibility, patients will be
randomised on a 1:1 basis to receive either rituximab
or placebo infusion, in addition to standard therapy.
Randomisation will be performed using minimisation
incorporating a random element, to ensure treatment
groups are well-balanced for: Centre; Age (≥65 or <65);
Disease Duration (≥10years or <10years); Consent for
minor labial gland biopsy; Consent for ultrasound scan.
Both registration and randomisation will be performed
centrally using an automated 24-hour telephone system
based at the Leeds Clinical Trials Research Unit.
Participating research sites will be required to complete
a log of all patients over the age of 18 with PSS who
are not registered for screening nor randomised either
because they are ineligible or because they decline
participation.
Blinding
The double-blind status of the trial will be maintained
by ensuring rituximab and placebo infusion bags are
identical in appearance at the time of dispensing from
Pharmacy. Treatment allocation will only be known
to the trial pharmacy and the central safety team at
the CTRU. The Investigators and other members of
the site staff involved with the trial will remain
blinded to the allocation. All patients will receive the
same pre- and post-infusion medication, and the infu-
sion will be administered in the same way for both
groups.
Emergency unblinding is permitted where knowledge
of treatment allocation is necessary for the appropriate
medical management of the patient. This will be per-
formed by the safety team at the CTRU (during office
hours) or the local Pharmacy team (during out of office
hours). Causality and expectedness of Adverse Events/
Follow-up evaluations at weeks 36 and 48.
Local investigations: Blood tests, clinical assessments, questionnaires, urine dipstick and pregnancy test.  
Research blood samples to central lab (Bart’s & London). Chest X-ray and ECG at week 48.
Labial gland biopsy and ultrasound imaging in a subset of patients where site facilities permit (supplementary 
consent for labial gland biopsy and salivary gland ultrasound scan) at circa week 48.
Study completed
Patient returns to routine care
Baseline evaluations (within 14 days prior to start of treatment)
Physical examination; stimulated salivary flow; Schirmers I test; questionnaires;
Research blood samples to central lab (Bart’s & London)
Labial gland biopsy and ultrasound imaging in a subset of patients where site facilities permit (supplementary 
consent for labial gland biopsy and salivary gland ultrasound scan)
Randomise patient (via CTRU 24 hour randomisation system)
Primary Sjögren’s Syndrome
Fulfilling AECG Criteria
Fatigue & Dryness 
If diagnosis using AECG criteria is ≥ 10 years evidence of systemic involvement is required
Written and verbal information of the trial and informed consent
Register patient (via CTRU 24 hour registration system)
Full eligibility screen (within 28 days prior to start of treatment)
Rituximab 1000mg (Week 24 & 26)
Methylprednisolone, chlorpheniramine, 
paracetamol
Oral prednisolone days 2-7
Placebo infusion (Week 24 & 26
Methylprednisolone, chlorpheniramine, 
paracetamol
Oral prednisolone days 2-7
Follow-up evaluations at weeks 16 and 24.
Local investigations: Blood tests, clinical assessments, questionnaires, urine dipstick and pregnancy test.
Research blood samples to central lab (Bart’s & London)
Labial gland biopsy and ultrasound imaging in a subset of patients where site facilities permit (supplementary 
consent for labial gland biopsy and salivary gland ultrasound scan) at circa week16.
Placebo infusion (Day 1 & 15)
Methylprednisolone, chlorpheniramine, 
paracetamol
Oral prednisolone days 2-7
Rituximab 1000mg (Day 1 & 15)
Methylprednisolone, chlorpheniramine, 
paracetamol
Oral prednisolone days 2-7
Figure 1 TRACTISS trial flow diagram.
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patient received rituximab.Treatment schedule
Patients will receive two courses of rituximab or placebo.
Each course consists of two doses of rituximab or pla-
cebo by intravenous infusion, administered at a two-
week interval. The first course is at week 0 and week 2;the second course is at week 24 and week 26. See
Figure 2 for details of the treatment schedule.
Assessments, samples and data collection
All protocol-required assessments will be entered onto
paper case report forms at each site. All timings relate to
first dosing at Week 0 (Day 1). An assessment of response
is made at week 16, week 24, week 36 and week 48
(end of study).
Table 1 Eligibility criteria for randomisation into the
TRACTISS trial
Inclusion criteria
1 Aged between 18 and 80 years of age.
2 A confirmed diagnosis of primary Sjögren’s Syndrome by
AECG criteria.
3 Positive for anti-Ro auto-antibodies.
4 Patients with a diagnosis of primary Sjögren’s Syndrome
(by AECG criteria) with more than 10 years disease duration
must have at least one systemic feature of:
● Hypergammaglobulinaemia (IgG over 16)*, or
● Low complement C4*, or
● Cryoglobulinaemia
OR
● Active/past history since diagnosis of the following
(ascribed to Sjögren’s Syndrome):
○ Purpura/cutaneous vasculitis,
○ Lymphadenopathy,
○ Persistent parotid salivary gland swelling not
due to infection,
○ Peripheral neuropathy (previously documented
by nerve conduction tests),
○ Interstitial lung disease confirmed by HRCT,
○ Renal tubular acidosis requiring treatment,
○ CNS disease ascribed to Sjögren’s syndrome
(confirmed by MRI),
○ Myositis (CPK>2N and EMG or biopsy evidence
of myositis),
○ Inflammatory arthritis
5 An unstimulated salivary flow rate greater than 0 ml in 15 minutes.
6 Symptomatic oral dryness (≥ 5/10 on patient-completed Likert**).
7 Symptomatic fatigue (≥ 5/10 on patient-completed Likert**).
8 Patients on corticosteroids, NSAIDS, antidepressants, DMARDs (e.g.
methotrexate, hydroxychloroquine, azathioprine, MMF, leflunomide,
ciclosporin etc.), or pilocarpine*** must have been on a stable dose
for 4 weeks prior to receiving the first infusion of study medication and
expected to remain on this dose throughout the study. If they have
stopped any of these drugs they should have been off it for at least 4
weeks prior to receiving study medication.
9 Given their written informed consent to participate in the trial
and expected to be able to adhere to the study visit schedule
and other protocol requirements.
*Anti-Ro antibody test, IgG, RF and C4 assays performed within 6
months of screening may be used to confirm eligibility. If greater
than 6 months repeats should be performed locally at screening
to confirm eligibility.
**LIKERT range 0-10 with 10 corresponding to worst severity.
***Pilocarpine or drugs with similar pharmacological action should
not be used within 12 hours of the assessment visits at screening,
baseline, week 16, week 24, week 36 and week 48 (end of study).
Table 1 Eligibility criteria for randomisation into the
TRACTISS trial (Continued)
Exclusion criteria
Patients will be excluded from the trial for the following reasons:
1 Diagnosis of secondary Sjögren’s Syndrome.
2 Pregnancy, lactation or women of child-bearing potential (WCBP)
unwilling to use medically approved contraception whilst receiving
treatment and for 12 months after treatment has finished.
3 Men whose partners are of child-bearing potential but who are unwilling
to use appropriate medically approved contraception whilst receiving
treatment and for 12 months after treatment has finished.
4 Patient has active or prior hepatitis B or C, known HIV positivity or
known history of tuberculosis.
5 Immunodeficiency or neutropaenia <1.5 × 109/l (unless a diagnosis
of benign ethnic neutropaenia has been confirmed in which case
the neutrophil count must be > 0.9 × 109/l at screening for
Jamaican and Afro-Caribbean populations [16]).
6 Any AECG exclusion criteria not covered elsewhere (graft versus
host disease, primary lymphoma excluding PSS, sarcoidosis).
7 Any malignancies that would normally preclude the use of rituximab
within the past 5 years, including solid tumours, haematological
malignancies and carcinoma in situ (except basal cell or squamous
cell carcinoma of the skin that has been excised and cured).
8 Participation in a clinical study involving administration of an
investigational drug within the past 4 weeks prior to the first infusion.
9 A history of major surgery within 3 months prior to first infusion or
planned surgery during the study.
10 Receipt of live/attenuated vaccine within 4 weeks prior to the
first infusion.
11 Previous exposure to rituximab or any other monoclonal antibody
within the past 5 years.
12 History of recurring or chronic infections or underlying conditions
which may further predispose patients to serious infection.
13 History of moderate to severe congestive heart failure according
to the New York Heart Association (NYHA) functional classification
system or other uncontrolled heart disease, or who have a clinically
significant abnormal ECG at the time of screening.
14 History of receiving human/murine recombinant products or known
allergy or anaphylactic reaction to a biologic agent or any component
of the active substance or any of its excipients or murine components.
15 Patients with fibromyalgia or a diagnosis of significant depression
or anxiety that in the opinion of the clinician would confound the
interpretation of the study results.
16 Current or a history of severe, progressive or uncontrolled renal,
hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac,
neurologic, or cerebral disease (including demyelinating diseases
such as multiple sclerosis).
17 Any history of organ transplant (with the exception of a corneal
transplant >3 months prior to study entry).
18 Presence of a clinically significant illness or mental disorder within
4 weeks of the start of the trial where the safety of the individual
might be at risk by entry into the trial, or where the individual does
not have the capacity to consent or where the outcome of the
therapy cannot be assessed by virtue of the illness or disorder. Each
patient will be assessed individually and no person who wishes to
participate will be unreasonably excluded by virtue of the illness
or disorder.
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Pre-infusion medication:
100mg (IV) Methylprednisolone  
commenced 30-60 mins prior to infusion
1g Paracetamol 60 mins prior to infusion
4mg Chlorophenamine 60 mins prior to 
infusion
Initial dose rate: 50mg/hour for 30 minutes
No adverse events
1st infusion (week 0 and 24):
Dose escalated every 30 
minutes in steps of 50mg/hr 
to 400mg/hour
2nd infusion (week 2 and 26):
Dose escalated every 30 
minutes in steps of 100 
mg/hr to 400mg/hour
Transient fever and rigours 
experienced
If symptoms resolve, 
infusion recommences at 
half the previous rate
Infusion temporarily 
discontinued and treatment 
administered as required
Post-infusion medication:
Oral prednisolone:
60mg  on days 2 -3 post infusion
30mg on days 4-5 post infusion
15mg on days 6-7 post infusion
Rituximab:
1000mg in 250ml 
Sodium Chloride 0.9%
Placebo:
250ml Sodium Chloride 
0.9%
Figure 2 Treatment schedule.
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 Screening visit: All patients will undergo
screening within 28 days prior to the start
of treatment.
 Baseline visit: Baseline assessments are to be
performed after eligibility has been confirmed and
within 14 days prior to the start of treatment.
 Treatment visits: All treatment visits will take
place at weeks 0, 2, 24 and 26. Assessment visits: Patients will be assessed at
weeks 16, 24, 36 and 48 for safety and outcome
measures and 7 days prior to dosing at weeks 24
for safety.
 Biological samples collected from participants
will be sent to the Central Laboratory at the
William Harvey Research Institute, London for
processing, appropriate analysis and storage.
These samples will be used for a range of studies of
direct relevance to the treatment of PSS.
Visit Screening Baseline Visit 1 -Treatment
Visit 2 -
Treatment
Visit 3 -
Assessment
Visit 4  -
Midpoint 
assessment
Visit 5 -
Treatment
Visit 6 -
Treatment
Visit 7 -
Assessment
Visit 8 –
End of study 
assessment
Assessment (Procedure / Activity)
Week -4    
(+14 
days)
Week  -2   
(+ 14 
days)
Week 0 Week 2(+ 7 days)
Week 16
(+/- 7 days)
Week 24        
(-7 days)4
Week 24  
(+/- 7 
days)
Week 26
(+ 7 days)
Week 36
(+/- 7 days)
Week 48 
(-/+ 7 days)
Informed consent & Registration x
Randomisation x
Rituximab / placebo x x x x
Vital signs x x x x
Demographics & Medical History x1
Pregnancy Test x x x
Physical examination x x x
Chest X-ray & ECG x6 x
VAS Scales (Fatigue & Oral dryness) x
Unstimulated Whole Salivary flow x x x x x
Stimulated Whole Salivary flow x x x x x
Schirmers I test x x x x x
Patient  and  Physician Questionnaires x x x x x
Health Economics Patient  & Physician 
Questionnaires x x x x
Local Samples
Immunology bloods 1 (IB1) x x 7 x 7 x 7 x 7
Routine blood tests 1 (RB1) x5 x x x x
Routine blood tests 2 (RB2) x x
Routine blood tests 3 (RB3) x x x
Routine blood tests 4 (RB4) x
Bence-Jones Protein x x x
Central Samples
Immunology bloods 2 (IB2) x2 x x x x
Immunology bloods 3 (IB3) x x x
Immunology bloods 4 (IB4) x x x x x
Biobank sample 1 (BB1) x
Biobank sample 3 (BB3) x x x x x
Safety evaluation Monitor during study treatment and 30 days after the last dose of protocol treatment
Labial gland biopsy  (BB23) x x x
Salivary gland ultrasound scans3 x x x
Figure 3 Schedule of events.
Brown et al. BMC Musculoskeletal Disorders 2014, 15:21 Page 7 of 10
http://www.biomedcentral.com/1471-2474/15/21Sample size
A total of 110 patients will be required for this study. A
sample size of 50 evaluable patients per treatment group
will provide 80% power to detect a difference in responserates of 30% corresponding to 25% on placebo and 55%
on rituximab, assuming a 2-sided 5% significance level. 50
patients per group will also provide at least 80% power to
detect a between group difference of 30% if the placebo
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rituximab). In order to allow for a 10% attrition rate, 110
patients will be randomised.
Outcomes
The primary outcome is achievement of a 30% reduction
at 48 weeks from baseline in either oral dryness or fa-
tigue measured using visual analogue scales (VAS -
Range 0-100 mm).
Secondary outcomes at weeks 16, 24, 36 and 48 are:
the values of the fatigue and oral dryness scales (VAS),
ocular dryness (VAS), patient global assessment of
health (VAS), physician global assessments of disease
activity and disease damage (0–10 Likert scales), stimu-
lated and unstimulated salivary flow rates, lacrimal flow
(Schirmers I test of ocular function), and the EULAR
Sjögren’s Syndrome Patient Reported Index (ESSPRI).
In addition, further quality of life, and disease damage
and disease activity indices at weeks 24 and 48 will be:
Medical Outcomes Survey Short Form (SF-36), EQ-5D,
EULAR Sjögren’s Syndrome Disease Activity Index
(ESSDAI), and the Profile of Fatigue and Discomfort –
Sicca Symptoms Inventory (PROFAD-SSI). Outcomes
relating to systemic disease activity features at weeks
24 and 48 are: Sjögren’s Syndrome Clinical Activity
Index (SCAI), Sjögren’s Syndrome Disease Activity
Index (SSDAI), Sjögren’s Syndrome Disease Damage
Index (SSDDI), and Sjögren’s Syndrome Damage Index
(SSDI). Further outcomes correspond to serological and
peripheral blood biomarkers (haematology, biochemistry,
serology and immunology assays) measured at each visit.
Both patients and physicians complete an exit poll at
week 48 asking them if they have suspicions as to which
treatment the patient received. Outcomes relating to the
optional sub-studies (Glandular histology and composition
assessed by biopsy and ultrasound respectively) will be
measured at weeks 16 and 48, and the T-Cell sub-study
outcomes (peripheral and lesional T cells) will be assessed
at week 16 for analysis in this study with samples taken at
weeks 24, 36 and 48 for use in future studies.
Statistical analysis
All analyses will be conducted on the intention-to-treat
(ITT) population and patients will be analysed according
to the treatment group to which they were randomised.
All formal analyses will be carried out at a 2-sided 5%
level of significance.
Primary outcome analyses
A binary logistic regression approach will model the odds
of achieving a 30% reduction in symptoms for patients
receiving rituximab compared to placebo. Models will
include baseline scores for oral dryness and fatigue, as
well as disease duration (≤10 years/>10 years), age andcentre. The estimated odds ratio for treatment effect will
be presented, with the associated 95% confidence interval,
and p-value from a likelihood ratio test comparing the
models with and without the treatment variable. In
addition, the number and proportion of patients in both
the rituximab and placebo groups who achieve a reduction
in either oral dryness or fatigue >30% between the end
of study visit (week 48) and the baseline visit will be
summarised. Multiple imputation will be used to im-
pute missing primary endpoint data.
Secondary outcome analyses
 Fatigue, oral and ocular dryness, patient and
physician global assessments: For each symptom, a
multi-level repeated measures linear regression
model will be used to compare VAS scores between
groups, models will include the minimisation factors
(age, centre, disease duration).
 Salivary and Lacrimal Flow: The flow rates
(stimulated salivary flow, unstimulated salivary flow,
lacrimal flow) will be compared between the
treatment groups using a multi-level repeated
measures linear regression model, models will
include the values at baseline and the minimisation
factors.
 Quality of Life and Disease Activity Indices: The
change in each Quality of Life Score, from baseline
to 24 and 48 weeks, as measured by SF-36 and each
Disease Activity Index (ESSDAI, ESSPRI, SF-36 and
PROFAD-SSI) will be compared between treatment
groups using a linear regression model, including
baseline score values and the minimisation factors.
 Safety and toxicity: Safety analyses will summarise
the adverse events (including serious adverse events
(SAEs), serious suspected adverse reactions and
suspected unexpected serious adverse events),
laboratory changes and treatment-related mortality
rates. Safety data will be presented by treatment group
and relationship to study treatment or underlying
PSS. Expected SAEs related to rituximab include
infusion-related reactions, infections, cardiovascular
events, hepatitis B reactivation and Progressive
Multifocal Leukoencephalopathy.
Exploratory analyses
Systemic disease activity features: Recently developed
measures (SCAI, SSDAI, SSDDI and SSDI) will be sum-
marised for each time-point at which they were measured.
Economic evaluation
The primary objective of the economic evaluation is to
identify the within study incremental cost effectiveness
ratios; the difference in costs between rituximab and
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mab and placebo. Analysis will use quality adjusted life
years (QALYs) as the summary measurement of benefits.
The estimation of QALYs requires the production of utility
weights for each health state observed in the trial popula-
tion. The EQ-5D (Euroqol) instrument will be used for this
purpose and estimation of QALYs will use the area under
the curve method [17,18]. Secondary analysis will use the
SF-36. Resource utilisation will be captured at 16, 24, 36
and 48 weeks after randomisation.
Sensitivity analysis of the incremental cost effectiveness
ratio will be undertaken. Bootstrapped incremental costs
and benefits will be calculated and used to estimate their
joint distribution. These estimates will form a scatter-
plot on the cost effectiveness plane, and will be used to
estimate a 95% cost effectiveness ellipse for the joint
distribution of increments costs and benefits, as well as
the cost effectiveness acceptability curve for a range of
values that a service provider may be willing to pay for
one additional QALY. Given the duration of the study
discounting is not required.
Discussion
PSS is characterised by oral and ocular dryness, severe
fatigue with reduced quality of life, B-cell hyperactivity,
anti-Ro/La antibodies and a 44 times increased risk of
B-cell lymphoma. There is no effective systemic therapy
that can alter the progress of the disease and no immedi-
ate prospect of commercial studies.
This protocol describes a phase III study of 110 patients
treated with either rituximab or placebo with re-treatment
at 6 months. Although small for a phase III trial it has
realistic recruitment and outcome objectives given the
prevalence of Sjögren’s syndrome, and it will be the lar-
gest trial conducted in the UK to date. Furthermore,
the broadly similar patient population and design of the
French study by Saraux et al. [13] should allow for future
meta-analysis of the data.
In parallel with the clinical outcomes of improvement
in fatigue and/or dryness the TRACTISS study includes
a number of biological outcomes including glandular
immunohistochemistry and genetic features, alteration in
anti-muscarinic antibody levels, peripheral T-cell numbers
and transcriptional profile, and BAFF/BLyS levels. The
availability of anti-B-cell therapy for RA means we can
also study whether it works in treating the debilitating
symptoms of PSS and this is the goal of this study. In
addition we will maximise the benefit of the study by also
measuring changes in the glands and blood of patients
through additional scientific research work that will add
support to the clinical findings.
If the results of this study are positive this could lead
to anti-B-cell therapy becoming part of routine clinical
care for patients with PSS and/or opening new avenuesfor developing alternative disease-modifying therapeutic
approaches for a disease that currently has none avail-
able. The incorporated integral scientific components of
TRACTISS will maximize the added value of the study to
better understand the pathological processes by looking at
the effects of rituximab on the glands, blood cells and
antibodies in PSS and guide future therapeutic research.
Trial status
The first patient was enrolled into TRACTISS on the 25th
August 2011 and recruitment is due to end December
2013. The study is being conducted in 25 sites across the
UK. We expect to report the main trial results in Autumn
2015. Ethical and governance approval for this trial has
been obtained from the Leeds West Ethics Committee (ref
10/H1307/99) and the Leeds Teaching Hospitals NHS
Trust respectively. The trial progress is monitored by an
independent Data Monitoring and Ethics Committee
(DMEC) and Trial Steering Committee (TSC).
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